达安基因(002030) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥169,136,638.98, a decrease of 14.71% compared to ¥198,307,676.45 in the same period last year[5] - Net profit attributable to shareholders was ¥52,924,282.00, a significant increase of 114.57% from a loss of ¥363,290,638.81 in the previous year[5] - Basic and diluted earnings per share were both ¥0.04, representing a 115.38% increase from -¥0.26 in the same period last year[5] - Operating profit turned positive at ¥93.18 million compared to a loss of ¥433.31 million in the previous period[28] - Net profit for the period was ¥51.26 million, a significant recovery from a net loss of ¥361.14 million in the prior year[28] - The company reported a total comprehensive income of ¥51.22 million, recovering from a loss of ¥360.92 million in the previous year[29] Cash Flow - The net cash flow from operating activities improved by 59.14%, reaching -¥36,693,867.25 compared to -¥89,798,669.28 in the previous year[5] - The net cash flow from operating activities was CNY -36,693,867.25, a 59.14% improvement compared to CNY -89,798,669.28 in the previous year, mainly due to reduced salary and bonus payments[13] - Cash flow from operating activities showed a net outflow of ¥36.69 million, an improvement from a net outflow of ¥89.80 million in the previous period[31] - The net cash flow from investing activities was CNY 43,714,694.14, a 142.95% increase from CNY -101,776,732.65 in the previous year, attributed to the maturity of large deposits and recovery of investment cash[13] - Cash inflow from investment activities was ¥580.96 million, compared to ¥137.93 million in the prior year, indicating a strong recovery[31] - Cash outflow for investment activities increased to ¥537.25 million from ¥239.71 million, reflecting increased investment efforts[31] - The net cash flow from financing activities decreased to CNY -27,698,161.40, a 260.01% decline compared to CNY -7,693,688.13 in the previous year, primarily due to increased cash payments for debt repayment[13] - Net cash flow from financing activities was -$27.70 million, compared to -$7.69 million in the previous period, indicating a significant decline[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,487,572,269.44, a decrease of 0.93% from ¥9,576,915,691.47 at the end of the previous year[5] - Total current assets decreased to CNY 3,296,019,612.54 from CNY 3,781,514,679.73, a decline of about 12.8%[22] - Total liabilities decreased to CNY 1,293,326,789.33 from CNY 1,433,894,606.08, representing a reduction of approximately 9.8%[24] - Total equity attributable to shareholders increased to CNY 7,932,851,074.19 from CNY 7,879,949,193.44, showing a growth of about 0.67%[24] - Non-current assets totaled CNY 6,191,552,656.90, up from CNY 5,795,401,011.74, indicating an increase of about 6.8%[22] Shareholder Information - The company had a total of 146,867 common shareholders at the end of the reporting period[15] - The largest shareholder, Guangzhou Guangyong Technology Development Co., Ltd., holds 16.63% of the shares, totaling 233,391,995 shares[16] - The second-largest shareholder, Guangzhou Biomedical and Health Industry Investment Co., Ltd., owns 10.00% of the shares, totaling 140,344,607 shares[16] Operational Costs - Operating costs increased by 33.18% to ¥116,639,813.97, primarily due to increased amortization of long-term assets related to production[12] - Total operating costs increased to ¥238.18 million from ¥207.95 million, representing a growth of approximately 14.8% year-over-year[27] - Sales expenses rose significantly by 78.43% to ¥45,354,577.50, mainly due to reclassification of expense categories[12] Other Income and Fair Value - The company reported a significant increase in other income, reaching CNY 793,129.91, a 526.82% rise compared to CNY 126,532.41 in the previous period, mainly due to increased penalty income[13] - The company recorded a significant fair value gain of ¥200.73 million, contrasting with a loss of ¥365.57 million in the previous period, highlighting improved market conditions[27] Future Plans and Developments - The company has announced plans to obtain a medical device registration certificate, indicating ongoing efforts in product development[18] - The company plans to hold an online explanation meeting for the 2024 annual report, indicating a commitment to transparency and communication with stakeholders[20] - The company plans to implement new accounting standards starting in 2025, which may impact financial reporting[34] Miscellaneous - The first quarter report was not audited, which may affect the reliability of the financial data presented[33] - Current cash and cash equivalents amount to CNY 851,296,028.53, down from CNY 872,086,093.74 at the beginning of the period[21] - Accounts receivable decreased to CNY 1,171,534,622.86 from CNY 1,254,344,767.52, reflecting a reduction of approximately 6.6%[21] - Inventory increased to CNY 202,660,100.27 from CNY 198,214,544.62, reflecting a rise of approximately 2.3%[22] - Short-term borrowings decreased to CNY 117,637,389.36 from CNY 143,534,033.02, a decline of approximately 18%[23] - Cash and cash equivalents net increase was -$20.78 million, compared to a much larger decrease of -$199.21 million in the previous period[32] - The company reported a decrease in cash flow due to foreign exchange fluctuations, amounting to -$100,827.82[32]